Asporin participates in gastric cancer cell growth and migration by influencing EGF receptor signaling

Ding,Qian; Zhang,Mei; Liu,Can

doi:10.3892/or.2015.3791

Asporin participates in gastric cancer cell growth and migration by influencing EGF receptor signaling

Authors:
- Qian Ding
- Mei Zhang
- Can Liu
View Affiliations

Affiliations: Department of Ultrasound, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei 434000, P.R. China
Published online on: February 9, 2015 https://doi.org/10.3892/or.2015.3791
Pages: 1783-1790

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Asporin (ASPN), a novel member of the small leucine-rich proteoglycan (SLRP) family, serves as a key component of the tumor stroma and has been reported to be abnormally expressed in certain types of tumors. Specifically, the proteoglycan was proven to activate the coordinated invasion of scirrhous gastric cancer and cancer-associated fibroblasts. However, the role of ASPN in cancer cell growth and metastasis has not yet been addressed. In the present study, we aimed to evaluate the tumoricidal benefits of ASPN on tumorigenesis and progression of gastric cancer. Firstly, it was demonstrated that ASPN was overexpressed in gastric carcinoma tissues when compared to the corresponding non‑cancerous tissues, and it had varied levels of expression in gastric cancer epithelial cell lines. Additionally, we assessed the effects of transient siRNA‑mediated ASPN knockdown on gastric cancer cells. ASPN silencing inhibited proliferation and suppressed the migration of immortalized neoplastic epithelial cells. Furthermore, at the molecular level, we found that downregulation of ASPN blocked the anti-apoptotic molecule Bcl-2, increased the expression of pro-apoptotic molecule Bad, reduced the expression of migration-related proteins CD44 and matrix metalloproteinase (MMP)-2, and abrogated the activation of the phosphorylation status of ERK and epidermal growth factor (EGF) and its receptor (EGFR). Collectively, our findings indicate that ASPN is upregulated and plays an oncogenic role in gastric cancer progression and metastasis by influencing the EGFR signaling pathway.

View Figures

View References

1	Hartgrink HH, Jansen EP, van Grieken NC and van de Velde CJ: Gastric cancer. Lancet. 374:477–490. 2009. View Article : Google Scholar : PubMed/NCBI
2	Zhang Z, Miao L, Xin X, et al: Underexpressed CNDP2 participates in gastric cancer growth inhibition through activating the MAPK signaling pathway. Mol Med. 20:17–28. 2014. View Article : Google Scholar : PubMed/NCBI
3	Sampieri CL, León-Córdoba K and Remes-Troche JM: Matrix metalloproteinases and their tissue inhibitors in gastric cancer as molecular markers. J Cancer Res Ther. 9:356–363. 2013. View Article : Google Scholar : PubMed/NCBI
4	Grivennikov SI, Greten FR and Karin M: Immunity, inflammation, and cancer. Cell. 140:883–899. 2010. View Article : Google Scholar : PubMed/NCBI
5	Canavese G, Candelaresi G, Castellano I and Mano MP: Expression of proteoglycan versican in in situ breast lesions: relations between stromal changes, histotype, and invasion. Pathol Res Pract. 207:97–103. 2011. View Article : Google Scholar
6	Lorenzo P, Aspberg A, Onnerfjord P, et al: Identification and characterization of asporin. A novel member of the leucine-rich repeat protein family closely related to decorin and biglycan. J Biol Chem. 276:12201–12211. 2001. View Article : Google Scholar : PubMed/NCBI
7	Satoyoshi R, Kuriyama S, Aiba N, et al: Asporin activates coordinated invasion of scirrhous gastric cancer and cancer-associated fibroblasts. Oncogene. 34:650–660. 2015. View Article : Google Scholar
8	Theocharis AD, Vynios DH, Papageorgakopoulou N, et al: Altered content composition and structure of glycosaminoglycans and proteoglycans in gastric carcinoma. Int J Biochem Cell Biol. 35:376–390. 2003. View Article : Google Scholar : PubMed/NCBI
9	Hu L, Duan YT, Li JF, et al: Biglycan enhances gastric cancer invasion by activating FAK signaling pathway. Oncotarget. 5:1885–1896. 2014.PubMed/NCBI
10	Wang B, Li GX, Zhang SG, et al: Biglycan expression correlates with aggressiveness and poor prognosis of gastric cancer. Exp Biol Med (Maywood). 236:1247–1253. 2011. View Article : Google Scholar
11	Ansari D, Aronsson L, Sasor A, et al: The role of quantitative mass spectrometry in the discovery of pancreatic cancer biomarkers for translational science. J Transl Med. 12:872014. View Article : Google Scholar : PubMed/NCBI
12	Turtoi A, Musmeci D, Wang Y, et al: Identification of novel accessible proteins bearing diagnostic and therapeutic potential in human pancreatic ductal adenocarcinoma. J Proteome Res. 10:4302–4313. 2011. View Article : Google Scholar : PubMed/NCBI
13	Klee EW, Bondar OP, Goodmanson MK, et al: Candidate serum biomarkers for prostate adenocarcinoma identified by mRNA differences in prostate tissue and verified with protein measurements in tissue and blood. Clin Chem. 58:599–609. 2012. View Article : Google Scholar : PubMed/NCBI
14	Turashvili G, Bouchal J, Baumforth K, et al: Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer. 7:552007. View Article : Google Scholar : PubMed/NCBI
15	Kizawa H, Kou I, Iida A, et al: An aspartic acid repeat polymorphism in asporin inhibits chondrogenesis and increases susceptibility to osteoarthritis. Nat Genet. 37:138–144. 2005. View Article : Google Scholar : PubMed/NCBI
16	Kopp R, Rothbauer E, Ruge M, et al: Clinical implications of the EGF receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: evidence for new therapeutic options. Recent Results Cancer Res. 162:115–132. 2003. View Article : Google Scholar : PubMed/NCBI
17	Moon WS, Tarnawski AS, Chai J, et al: Reduced expression of epidermal growth factor receptor related protein in gastric cancer. Gut. 54:201–206. 2005. View Article : Google Scholar : PubMed/NCBI
18	Ashktorab H, Daremipouran M, Wilson M, et al: Transactivation of the EGFR by AP-1 is induced by Helicobacter pylori in gastric cancer. Am J Gastroenterol. 102:2135–2146. 2007. View Article : Google Scholar : PubMed/NCBI
19	Hwang YP, Yun HJ, Choi JH, et al: Suppression of EGF-induced tumor cell migration and matrix metalloproteinase-9 expression by capsaicin via the inhibition of EGFR-mediated FAK/Akt, PKC/Raf/ERK, p38 MAPK, and AP-1 signaling. Mol Nutr Food Res. 55:594–605. 2011. View Article : Google Scholar : PubMed/NCBI
20	Murphy KM, Ranganathan V, Farnsworth ML, et al: Bcl-2 inhibits Bax translocation from cytosol to mitochondria during drug-induced apoptosis of human tumor cells. Cell Death Differ. 7:102–111. 2000. View Article : Google Scholar : PubMed/NCBI
21	Wobus M, Rangwala R, Sheyn I, et al: CD44 associates with EGFR and erbB2 in metastasizing mammary carcinoma cells. Appl Immunohistochem Mol Morphol. 10:34–39. 2002. View Article : Google Scholar : PubMed/NCBI
22	Gurgel DC, Valença-Junior JT, Dornelas CA, et al: Immuno expression of metalloproteinases 2 and 14 and TIMP-2 inhibitor in main types of primary gastric carcinomas and lymph node metastasis. Pathol Oncol Res. 21:73–81. 2015. View Article : Google Scholar
23	Zhang Z, Zhang J, Miao L, et al: Interleukin-11 promotes the progress of gastric carcinoma via abnormally expressed versican. Int J Biol Sci. 8:383–393. 2012. View Article : Google Scholar : PubMed/NCBI
24	Schmidt M and Lichtner RB: EGF receptor targeting in therapy-resistant human tumors. Drug Resist Updat. 5:11–18. 2002. View Article : Google Scholar : PubMed/NCBI
25	Kolch W: Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol. 6:827–837. 2005. View Article : Google Scholar : PubMed/NCBI
26	Merline R, Schaefer RM and Schaefer L: The matricellular functions of small leucine-rich proteoglycans (SLRPs). J Cell Commun Signal. 3:323–335. 2009. View Article : Google Scholar : PubMed/NCBI
27	Shi M, Zheng D, Sun L, et al: XB130 promotes proliferation and invasion of gastric cancer cells. J Transl Med. 12:12014. View Article : Google Scholar : PubMed/NCBI
28	Khurana SS, Riehl TE, Moore BD, et al: The hyaluronic acid receptor CD44 coordinates normal and metaplastic gastric epithelial progenitor cell proliferation. J Biol Chem. 288:16085–16097. 2013. View Article : Google Scholar : PubMed/NCBI
29	Łukaszewicz-Zając M, Mroczko B, Guzińska-Ustymowicz K, et al: Matrix metalloproteinase 2 (MMP-2) and their tissue inhibitor 2 (TIMP-2) in gastric cancer patients. Adv Med Sci. 58:235–243. 2013. View Article : Google Scholar
30	Hwang TL, Changchien TT, Wang CC and Wu CM: Claudin-4 expression in gastric cancer cells enhances the invasion and is associated with the increased level of matrix metalloproteinase-2 and -9 expression. Oncol Lett. 8:1367–1371. 2014.PubMed/NCBI
31	Song YQ, Cheung KM, Ho DW, et al: Association of the asporin D14 allele with lumbar-disc degeneration in Asians. Am J Hum Genet. 82:744–747. 2008. View Article : Google Scholar : PubMed/NCBI
32	Tomoeda M, Yamada S, Shirai H, et al: PLAP-1/asporin inhibits activation of BMP receptor via its leucine-rich repeat motif. Biochem Biophys Res Commun. 371:191–196. 2008. View Article : Google Scholar : PubMed/NCBI
33	Cabello-Verrugio C and Brandan E: A novel modulatory mechanism of transforming growth factor-beta signaling through decorin and LRP-1. J Biol Chem. 282:18842–18850. 2007. View Article : Google Scholar : PubMed/NCBI
34	Zafiropoulos A and Tzanakakis GN: Decorin-mediated effects in cancer cell biology. Connect Tissue Res. 49:244–248. 2008. View Article : Google Scholar : PubMed/NCBI
35	Mohan RR, Tovey JC, Gupta R, et al: Decorin biology, expression, function and therapy in the cornea. Curr Mol Med. 11:110–128. 2011. View Article : Google Scholar : PubMed/NCBI
36	Morcavallo A, Buraschi S, Xu SQ, et al: Decorin differentially modulates the activity of insulin receptor isoform A ligands. Matrix Biol. 35:82–90. 2014. View Article : Google Scholar : PubMed/NCBI
37	Goldoni S, Iozzo RA, Kay P, et al: A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity. Oncogene. 26:368–381. 2007. View Article : Google Scholar
38	Judd NP, Winkler AE, Murillo-Sauca O, et al: ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res. 72:365–374. 2012. View Article : Google Scholar :
39	Chen Y, Zheng L, Liu J, et al: Shikonin inhibits prostate cancer cells metastasis by reducing matrix metalloproteinase-2/-9 expression via AKT/mTOR and ROS/ERK1/2 pathways. Int Immunopharmacol. 21:447–455. 2014. View Article : Google Scholar : PubMed/NCBI